Adaptive Biotechnologies Corporation ADPT
Set alert
At close · Oct 30
After hours · Oct 30, 4:12 PM ET
- YTD
- +64.04%
- 1 year
- +57.54%
- Open
- 27.36
- Prev close
- 28.17
- Mkt cap
- 4.25B
- Vol
- 4.26M
- Avg vol
- 2.17M
- EPS
- -0.41
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 26.17
- High
- 27.97
- Forward P/E
- -147.76
- Beta
- 2.10
- Short ratio
- 4.56
- Inst. own
- 99.06%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 26.35
- 200-d avg
- 19.56
- 1y target
- 30.21
5D chart
Signals (109)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 2 days ago |
| RSI: Oversold | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:20 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:20 PM | 2 days ago |
| RSI: Oversold | Oct 30, 12:00 PM | 2 days ago |
| RSI: Oversold | Oct 30, 11:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:50 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:45 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 2 days ago |
| RSI: Oversold | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 2:35 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:25 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 11:10 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:55 AM | 3 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:40 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 11:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:10 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:05 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:00 AM | 4 days ago |
| RSI: Overbought | Oct 28, 11:00 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:25 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:35 AM | 4 days ago |
| RSI: Overbought | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 3:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:40 PM | 5 days ago |
| RSI: Overbought | Oct 27, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:25 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:45 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:45 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 11:40 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:35 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:40 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:50 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 6 days ago |
News
5 days ago seekingalpha.com
Adaptive Biotechnologies: Getting Paid Every Step Of The Way To A Myeloma Cure
Adaptive Biotechnologies benefits from new NCCN guidelines and IMS cure definitions, positioning clonoSEQ as the standard for long-term myeloma MRD monitoring. MRD revenues grew 33% year-over-year to…
6 days ago defenseworld.net
Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 11,881 Shares of Company Stock
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) COO Julie Rubinstein sold 11,881 shares of the business's stock in a transaction on Friday, October 23rd. The shares were sold at…
6 days ago defenseworld.net
Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 11,881 Shares of Stock
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) COO Julie Rubinstein sold 11,881 shares of the firm's stock in a transaction on Monday, October 26th. The stock was sold at an…
6 days ago benzinga.com
MercadoLibre, Banco Bradesco, Itaú Unibanco And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Brazilian stocks plunged premarket after Lula's reelection, led by XP (-46%), Inter & Co (-34.7%), StoneCo (-33.8%) and MercadoLibre (-14.1%).
1 week ago seekingalpha.com
Alger Small Cap Focus Fund Q3 2026 Portfolio Update
Forte Biosciences Inc., Twist Bioscience Corp., and Adaptive Biotechnologies Corp., were among the top contributors to performance. Cardinal Infrastructure Group, Inc., RBC Bearings Incorporated, and…
2 weeks ago defenseworld.net
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $304,272.41 in Stock
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) COO Julie Rubinstein sold 11,881 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were…
2 weeks ago globenewswire.com
Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026
SEATTLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune…
-
2 weeks ago benzinga.com
TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32
TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $28 to $32.
-
2 weeks ago benzinga.com
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $27
Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $22 to $27.
2 weeks ago gurufocus.com
Adaptive Biotechnologies Corp (ADPT) Stock Down 3.5% but Still Overvalued -- GF Score: 68/100
On October 12, 2026, Adaptive Biotechnologies Corp (ADPT) shares fell 3.5%, currently trading at $25.57. The stock has seen significant volatility, with a 52-we
3 weeks ago defenseworld.net
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Rated “Moderate Buy” by Sell-Side Brokerages
Shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) have received an average rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm,…
3 weeks ago defenseworld.net
Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 52-Week High – Still a Buy?
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $30.10 and last traded at $30.3490, with…
-
1 month ago benzinga.com
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32
Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $32.
-
1 month ago benzinga.com
Goldman Sachs Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $35
Goldman Sachs analyst Evie Koslosky initiates coverage on Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy rating and announces Price Target of $35.
1 month ago globenewswire.com
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune…
1 month ago defenseworld.net
Financial Comparison: Charles River Laboratories International (NYSE:CRL) versus Adaptive Biotechnologies (NASDAQ:ADPT)
Adaptive Biotechnologies (NASDAQ: ADPT - Get Free Report) and Charles River Laboratories International (NYSE: CRL - Get Free Report) are both healthcare companies, but which is the superior business?…
-
1 month ago benzinga.com
BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34
BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $34.
1 month ago defenseworld.net
Adaptive Biotechnologies (NASDAQ:ADPT) Reaches New 1-Year High – Should You Buy?
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) shares hit a new 52-week high during trading on Tuesday. The company traded as high as $28.78 and last traded at $27.86, with a…
-
1 month ago benzinga.com
Adaptive Biotechnologies Highlights NCCN Guideline Updates Naming clonoSEQ For MRD Assessment In Multiple Myeloma
Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journeyclonoSEQ named as an FDA-cleared assay for MRD assessment, with 10-6…
1 month ago globenewswire.com
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10 -6…
1 month ago seekingalpha.com
Adaptive Biotechnologies Corporation (ADPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Adaptive Biotechnologies Corporation (ADPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago benzinga.com
ServiceTitan, Braze, Target Hospitality And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. futures were mixed; ServiceTitan plunged 16.7% on weak Q3 guidance, while Mind Technology, Braze and others also fell premarket.
2 months ago globenewswire.com
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune…
2 months ago defenseworld.net
Algert Global LLC Has $2.83 Million Position in Adaptive Biotechnologies Corporation $ADPT
Algert Global LLC decreased its position in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 63.7% during the undefined quarter, according to the company in its most recent filing with the SEC.…
2 months ago geekwire.com
Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science
Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode
2 months ago defenseworld.net
Dimensional Fund Advisors LP Cuts Stock Holdings in Adaptive Biotechnologies Corporation $ADPT
Dimensional Fund Advisors LP lowered its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 86.4% in the undefined quarter, according to its most recent Form 13F filing with…
-
2 months ago benzinga.com
Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5
Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price target from $20 to $27.5.
3 months ago seekingalpha.com
Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder
Adaptive Biotechnologies (ADPT) is transitioning to a pure-play MRD diagnostics company, with the spin-off of Immune Medicine revealing strong underlying profitability. MRD revenue grew 49%…
3 months ago zacks.com
Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?
Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
-
3 months ago benzinga.com
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $22
Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $20 to $22.
-
3 months ago benzinga.com
TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $28
TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $28.
-
3 months ago benzinga.com
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25
Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $22 to $25.
-
3 months ago benzinga.com
BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25
BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $24 to $25.
-
3 months ago benzinga.com
UPDATE: Adaptive Biotechnologies Q2 Adj. EPS $(0.10) Beats $(0.13) Estimate, Sales $71.553M Beat $65.886M Estimate
Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 41.18 percent increase over…
-
3 months ago benzinga.com
Adaptive Biotechnologies Q2 EPS $(0.25) Misses $(0.14) Estimate, Sales $71.553M Beat $65.886M Estimate
Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.14) by 78.57 percent. This is a 47.06 percent decrease over…
-
3 months ago benzinga.com
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $20
Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $18 to $20.
-
4 months ago benzinga.com
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $22
Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $21 to $22.
4 months ago benzinga.com
KB Home Posts Upbeat Q2 Sales, Joins Inmode, Icon And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rose, with Nasdaq up 50 points. KB Home (NYSE: KBH) reported strong Q2 results, shares jumped 16.2%. Other big gainers: WEN, ABSI, RUN, CCXI, ENRD, SFTX, ICCM, INMD, DFH.
4 months ago benzinga.com
Adaptive Biotechnologies Business Separation May Unlock Greater Value
William Blair says Adaptive's Immune Medicine separation could sharpen the MRD story, improve flexibility and support valuation.
-
4 months ago benzinga.com
BTIG Reiterates Buy on Adaptive Biotechnologies, Maintains $22 Price Target
BTIG analyst Mark Massaro reiterates Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and maintains $22 price target.
-
4 months ago benzinga.com
Adaptive Biotechnologies Prices $300M Upsized Convertible Notes Offering (Up From $250M)
Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT) today announced the pricing of its offering of $300 million aggregate principal amount of 0% convertible senior notes…
4 months ago benzinga.com
Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses
Adaptive Biotechnologies plans to separate its businesses as clonoSEQ profitability and revenue growth accelerate.
4 months ago benzinga.com
Stock Market Today: S&P 500, Nasdaq Futures Fall, Dow Gains Amid US-Iran Deal— SpaceX, Dave And Buster's, Western Digital In Focus (UPDATED)
(Editor’s note: The lede, headline, futures and economic data were updated.) U.S. stock futures were mixed on Tuesday, as the Dow Jones rose, while the Nasdaq 100 and S&P 500 declined, following…
4 months ago benzinga.com
Dave and Buster's Reports Downbeat Q1 Earnings, Joins Alvotech And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
US stock futures up 0.1%, Dave and Buster's (PLAY) down 13.4% pre-market due to lower earnings; other stocks declining in pre-market trading
4 months ago benzinga.com
Why High Tide Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
HITI rose sharply in pre-market trading on strong Q2 results and continued to rise after market open. Other gainers include SLBT, TDIC, IMCC, IVDA, NXTS, CRVO, PAVS, ALBT, and PURR. Losers include…
4 months ago benzinga.com
John Wiley & Sons, Dave and Buster's Entertainment And 3 Stocks To Watch Heading Into Tuesday
Stock futures lower, Wiley & Sons and Vince Holding expected to report earnings, Dave & Buster's and Adaptive Biotechnologies saw after-hours trading dips.
-
8 months ago benzinga.com
Earnings Scheduled For February 5, 2026
Earnings Scheduled For February 5, 2026
9 months ago benzinga.com
Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday
Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday
11 months ago benzinga.com
Ross Stores Posts Strong Q3 Results, Joins Enviri, Azenta And Other Big Stocks Moving Higher On Friday
Ross Stores Posts Strong Q3 Results, Joins Enviri, Azenta And Other Big Stocks Moving Higher On Friday